Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

July 6, 2018

Study Completion Date

March 31, 2020

Conditions
Localized Prostate Cancer
Interventions
DRUG

Ad5-SGE-REIC/Dkk3

Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.

Trial Locations (3)

77030

The Methodist Hospital Research Institute, Houston

92093

UCSD Moores Cancer Center, San Diego

02115

Brigham and Women's Hospital, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

The Pacific Link Consulting Co

OTHER

lead

Momotaro-Gene Inc.

INDUSTRY

NCT01931046 - Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer | Biotech Hunter | Biotech Hunter